New Drug Partially Restores Light Sensitivity in Patients With Inherited Blindness

Researchers at the University of Adelaide have reported the first successful human trial of a novel treatment for retinitis pigmentosa, one of the leading causes of irreversible blindness in working-age adults. The early clinical findings, published in Nature Medicine, suggest the therapy may partially restore light sensitivity in patients with advanced retinal degeneration.

Retinitis pigmentosa is an inherited disorder in which the retina's light-sensitive photoreceptor cells gradually die, leading to progressive vision loss. Until now, effective treatment options for advanced stages of the disease have been extremely limited.

The new approach is based on a photoswitch molecule that is injected directly into the eye. Once administered, the compound enables the remaining retinal cells to become light-sensitive again, even after the natural photoreceptors have been lost.

The clinical trial was conducted by researchers from the University of Adelaide in collaboration with the University of Washington. Initially designed as a small pilot study to evaluate the treatment's safety, the trial also produced encouraging signs of improved visual function in several participants.

Some patients achieved better scores on vision tests, including tasks involving navigation and walking. One volunteer with severe retinal degeneration reported a noticeable improvement in light perception just two days after receiving the injection.

"What began as a small safety study has now opened the door to an entirely new approach for treating degenerative eye diseases," said the study's lead investigator, Professor Robert Casson.

According to Casson, this is the world's first clinical trial of a photoswitch therapy in humans.

"Unlike gene therapy, which is designed for specific genetic mutations, this approach could potentially be applied to many different forms of retinal degeneration. It also does not require genetic modification, making treatment simpler and potentially reducing associated risks," he explained.

The researchers reported that the treatment was well tolerated. Throughout the study, no serious adverse events or signs of eye damage were observed.

In addition to patients' subjective reports of improved vision, the team also obtained objective evidence of the treatment's biological activity. Functional brain imaging showed activation of the visual cortex following administration of the drug.

"We have seen the first indications that the treatment is producing a genuine biological effect. Some participants experienced improved light perception, and brain imaging confirmed activation of visual processing areas after treatment. However, these are preliminary findings that must be confirmed in larger clinical studies," Professor Casson said.

A Phase II clinical trial is already underway to determine whether the therapy can produce meaningful improvements in vision for patients with retinitis pigmentosa. The researchers believe the technology may eventually be applicable to other degenerative retinal diseases as well.